Fig. 6

Inhibition of ITK expression enhanced chemosensitivity to common chemotherapeutic agents in malignant T cells. Tumor cells transfected with shITK (shITK-34465, shITK-34466 and shITK-34467) or shControl were exposed to vincristine (a) or doxorubicin (b) for 72 h. Cell viability was measured using a Cell Titer-Glo Luminescent Cell Viability Assay. c Tumor cells were seeded in opaque-walled 96-well plates at a density of 4 × 10⁴ cells/ml and incubated with varying, minimally toxic concentrations of BMS-509744 in the presence or absence of fixed concentrations of vincristine (Jurkat, 0.01 μM; Hut-78, 0.01 μM; H9, 0.001 μM) for 72 h. d Tumor cells were incubated with varying minimally toxic concentrations of BMS-509744, in the presence or absence of fixed concentrations of doxorubicin (Jurkat 0.1 μM, Hut-78 0.1 μM and H9 0.04 μM) for 72 h. The cell viability was measured using the Cell Titer-Glo Luminescent Cell Viability Assay. Inhibition rates were calculated by (1 − Dosing/Vehicle) × 100%. e The CI values at different concentrations of BMS-509744 with fixed concentrations of vincristine or doxorubicin in malignant T cells were calculated using CalcuSyn software. VCR vincristine, DOX doxorubicin. Data are expressed as Mean ± SD and representative of three independent experiments. Statistical analysis was performed using Student’s t test. *P < 0.05, **P < 0.001 compared with the control group